From September 8 to 11, Sochi hosted a specialized event for obstetricians-gynecologists, neonatologists and doctors of related specialties - “Russia’s reproductive potential: versions and contraversions”. It was one of the most popular and large-scale events dedicated to women’s and family health.

The Pharmasyntez Group of Companies introduced the seminar attendees to the lines of hormonal medicines DlyaJens and PlaniJens, and also co-organized “Women’s health: to preserve, to return, not to lose…” symposium, during which Russian lead specialists spoke about women’s diseases associated with hormonal imbalance and modern therapy methods.

The importance of DlyaJens Metri medicine for the treatment of endometriosis, for instance, was discussed by Elena Nikolayevna Andreyeva, Professor and Doctor of Medical Sciences.

“Endometriosis is quite a wide-spread condition. It occurs in approximately 10% of women of reproductive age. Endometriosis can occur in women of any age, but it is most often diagnosed in women between the ages of 25 and 40. If not treated on time, endometriosis can lead to a number of negative consequences, including infertility. DlyaJens Metri medicine will help provide an affordable endometriosis therapy,” said Elena Andreyeva.

Marina Borisovna Khamoshina, Professor and Head of the Obstetrics, Gynecology and Reproductive Medicine Department of the RUDN University Faculty of Medical Workers Advanced Training, spoke about climax hormonal therapy, which aims at reducing or eliminating the symptoms of menopause for women. The therapy includes the use of estrogen and progesterone hormones. Pharmasyntez produces 2 medicines for this group of female patients – DlyaJens Klimo and DlyaJens Estri.